Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 plus Anlotinib vs Pembrolizumab in Advanced NSCLC
NCT04964479Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing TQB2450 + Anlotinib with Pembrolizumab + Placebo (2 arms). Primary endpoint: Progression-Free Survival up to 2 years. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04964479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04964479.